Clinical pharmacokinetics of capecitabine

Clinical Pharmacokinetics

Volumn 40, Issue 2, 2001, Pages 85-104

  Reigner, Bruno ^a   Blesch, Karen ^b   Weidekamm, Erhard ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' DEOXY 5 FLUOROCYTIDINE; ALUMINUM MAGNESIUM HYDROXIDE; CAPECITABINE; CYTIDINE DEAMINASE; CYTIDINE DERIVATIVE; DOCETAXEL; DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; WARFARIN;

ANTINEOPLASTIC ACTIVITY; COLORECTAL TUMOR; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TUMOR LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0035076059     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140020-00002     Document Type: Review

References (58)

1. 5-Fluorouracil: A pharmacological paradigm in the use of cytotoxics
2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
3. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
4. Efficacy of intravenouscontinuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
5. A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma
6. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer
7. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology
8. Oral fluoropyrimidines in the treatment of colorectal cancer
9. The oral fluorouracil prodrugs
10. Capecitabine (Xeloda®), an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
11. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
12. A phase III trial (SO 14796) of Xeloda® (capecitabine) in previously untreated advanced/metastatic colorectal cancer
13. Aphase III trial (SO14695) of Xeloda® (capecitabine) in previously untreated advanced/metastatic colorectal cancer
14. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients
15. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
16. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
17. Influence of Maalox on the pharmacokinetics of capecitabine in cancer patients
18. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
19. A phase 1 study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer
20. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
21. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate
22. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implications in 5-fluorouracil chemotherapy
23. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
24. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency
25. Population study of dihydropyrimidine dehydrogenase in cancer patients
26. Clinical pharmacology of 5-fluorouracil
27. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors compared with plasma
28. Antitumor activity of 5′deoxy-5-fluorouridine in human digestive organ cancer xenografts and pyrimidine nucleoside phosphorylase activity in normal and neoplastic tisues from human digestive organs
29. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa
30. Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumor tissues of colon and liver in humans
31. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
32. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
33. Cellular pharmacology of fluorinated pyrimidines in vivo in man
34. Fluorouracil therapy in patients with carcinoma of large bowel: A pharmacokinetic comparison of various rates and routes of administration
35. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile
36. 14C-labelled drug
37. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
38. Noncompartmental analysis based on the statistical moment therapy
39. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
40. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
41. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
42. Relationships between metrics of exposure to Xeloda® and occurrence of adverse effects
43. Cytotoxics and irreversible effects
44. Drug interactions with quinolones
45. The effect of magnesium sulfate in lowering tetracycline blood levels
46. Effect of an antacid on gastrointestinal absorption of theophylline
47. Gastrointestinal cancers
48. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
49. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer
50. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
51. Studies with RP 56976 (Taxotere): A semisynthetic analog of Taxol
52. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts
53. Taxol, a microtubule stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukm-1 in macrophages
54. A matrix-designed phase I dose-finding and pharmacokinetic study of the combination of capecitabine (Xeloda®) and docetaxel (Taxotere®) in patients with advanced solid tumors
55. Warfarin-5-FU interaction: A consecutive case series